SCHEMBL20164568

SCHEMBL20164568

CNc1nc(NCC2CC2)nc2c(NC)nc(NCCO)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.50
MAPK1 P28482 3/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
HRH4 Q9H3N8 2/20 0.35
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
CDK1 P06493 4/20 0.34
CCNA2 P20248 2/20 0.33
CDK2 P24941 2/20 0.33
CCNA1 P78396 2/20 0.33
VCP P55072 2/20 0.33
IKBKB O14920 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CCNB2 O95067 1/20 0.33
CCNE2 O96020 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164307 0.99 SLC29A1 (0.49) SLC29A1MAPK1KMT2AGAAMEN1
SCHEMBL16094309 0.89 HRH4 (0.40) SLC29A1HRH4VCPKDM4E
Hydrochloric Acid SCHEMBL16093980 0.88 HRH4 (0.40) HRH4CDK2VCPKDM4E
SCHEMBL18360928 0.85 SLC29A1 (0.50) SLC29A1MAPK1USP2POLBCDK1
Hydrochloric Acid SCHEMBL20164577 0.84 SLC29A1 (0.49) SLC29A1MAPK1KMT2AGAAMEN1
SCHEMBL18826205 0.81 YTHDC1 (0.40) MAPK1HRH4VCPKDM4E
SCHEMBL20164463 0.80 CDK2 (0.37) HRH4CDK1CCNA2CDK2CCNA1
SCHEMBL20164464 0.80 CDK2 (0.37) HRH4CDK1CCNA2CDK2CCNA1
SCHEMBL20164481 0.80 CDK2 (0.37) HRH4CDK1CCNA2CDK2CCNA1
SCHEMBL20179388 0.80 SLC29A1 (0.66) SLC29A1MAPK1KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US claimed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885MAPK1 4681/4885KMT2A 2456/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885MAPK1 3271/4885KMT2A 1865/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885MAPK1 4702/4885KMT2A 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.